---
schema_version: "secwatch.filing_event.v1"
accession: "0001731122-26-001020"
form_type: "8-K"
ticker: "SBEV"
cik: "0001553788"
company_name: "SPLASH BEVERAGE GROUP, INC."
filed_at: "2026-08-05T12:35:42+00:00"
generated_at: "2026-08-05T12:40:08.972402+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Splash Beverage Group partners with Lupvindol Biosciences to advance CannEpil through FDA veterinary pathway

## Summary
- Collaboration targets companion-animal oncology and chronic pain management; canine applications are initial focus.
- Lupvindol CEO Hunter Land, Ph.D., led development of first FDA-approved plant-derived cannabinoid medicine Epidiolex.
- Global veterinary pain-management market valued at $2.6B in 2024, projected to reach $3.8B by 2030.
- Splash retains ownership of data, IP, and commercialization rights; provides milestone-based funding.
- Program aims for FDA Conditional Approval under Section 571 of FD&C Act; no assurance of approval.

## SEC filing metadata
- accession: 0001731122-26-001020
- form_type: 8-K
- ticker: SBEV
- cik: 0001553788
- company_name: SPLASH BEVERAGE GROUP, INC.
- filed_at: 2026-08-05T12:35:42+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1553788/000173112226001020/0001731122-26-001020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1553788/000173112226001020/e7828_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001731122-26-001020
- JSON: https://secwatch.observer/filing/0001731122-26-001020.json
- Plain text: https://secwatch.observer/filing/0001731122-26-001020.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.